November 2013 | Ophthalmology Innovation Source

EU Commercialization Strategies

Summit Co-Chair and Managing Director for InterWest Partners, Gilbert Kliman MD, captures the audience’s thoughts on commercialization strategies in Europe through a series of live polling questions. Also gaining the expert opinions of panelists, Laurent Attias, David Muller, David E.I. Pyott, Jim Mazzo and Andy Corley, Gil compares the who, what and where questions that…

2013 Ophthalmic Market – “Year in Review”

Emmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key accomplishments from many device and pharma companies, Emmett continues to expand on the present landscape with promising data to show that the ophthalmology market is stable despite the decrease in…

Ophthalmic Innovation Survives and Thrives After “The Great Recession”

Keynote: Sustaining Innovation in Ophthalmology – “A View From the Top” David E.I. Pyott, Chairman of the Board & CEO for Allergan, delivers a keynote presentation at the 5th Annual Ophthalmology Innovation Summit in New Orleans. Giving the audience a recap of the current stressors on pricing, David delves into the issue of taxes and…

Bill Link Dives into his Perspective of Venture Overseas

William J. Link PhD, Managing Director for Versant Ventures, gives the audience at the 5th Annual Ophthalmology Innovation Summit a look into the returns on the venture investing side and the comparison between the US and Europe. Utilizing specific data and numbers, Bill continues to share his personal biases as an American in the US…

Jonathan Norris Predicts a Positive Cycle in the Ophthalmic Private Market

Private Funding and Exit Trends Jonathan Norris, Managing Director for SVB Capital, takes the stage to share the positive sentiments on the private markets. Highlighting in detail venture healthcare funds, Series A and M&A, Jonathan predicts stability in fundraising dollars, while investment dollars in the companies will begin to decline, expanding on the important role…

PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving to decrease the burden of injections and injection related risks, Paul shares the company’s unique discovery that led to their many successes. Presenter: Paul Chaney Paul G. Chaney is Co-Founder,…

Ophthotech Introduces Their Antigen for WetAMD

David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the products successes, which have led to phase three testing and secured financing. Presenter: David Guyer, MD Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May…

iCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema

iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which is fully enrolled in the U.S. Viewing an opportunity to better serve this population, ICO Therapeutics talks about their products that provide improved outcomes for patients not responding or only…

Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s progress over the past year. Highlighting their company’s focus on understanding the biology of key targets in ophthalmic diseases and creating protein therapeutics to treat them, Abbie details the current…

Physician Entrepreneurship in Ophthalmology

Striving to reach the aspiring entrepreneurs in the crowd at the 5th Annual Ophthalmology Innovation Summit @ AAO in New Orleans, Dick Lindstrom leads an experienced panel of entrepreneurs and tech developers through a series of focused questions. Sharing their highly coveted successes and failures, these panelists cover all aspects of entrepreneurship from focusing in…

Ophthalmic Innovation 2013 – “A View from the AAO”

David Parke, CEO for the American Academy of Ophthalmology, speaks to the audience of the 5th Annual Ophthalmology Innovation Summit @ AAO, about the importance, benefits and overall successes surrounding the use of clinical registries, namely the IRIS Registry. Highlighting the value proposition for ophthalmologists, David shares the Academy’s hope for the registry to reduce…

Alternative Financing Strategies

Charles Warden, Managing Director for Versant Ventures, initiates this finance focused panel by detailing the funding gap that has been referred to often at the 5th Annual Ophthalmology Innovation Summit @ AAO. Gaining insights from Luke Duster of Capital Royalty, Gregory Shearer of Healthios Capital Markets, Brian Demmert of Armentum Partners and Buzz Benson of…